JLHL · Health Care · 2026-08-07

Jupiter Life Line Hospitals Ltd

Stage 4 · wk 2In scan: Prop Scan · Breakout WatchMARKET: BULL TOPPING · 2026-08-07
₹320.2
+0.30% today
₹10,497 Cr · Mid cap
About this companyHealth Care· Hospitals & Diagnostic Centres
Expand ▾

Jupiter Life Line Hospitals Limited, a multi-specialty hospital, provides health care services under the Jupiter brand in India. The company offers treatments in the areas of bariatric surgery, breast care center, cardiac surgery, cardiology, chest medicine, dental care, dermatology, endocrinology and diabetes, ENT, gastroenterology, general surgery and minimal access surgery, hematology and BMT, HPB and surgical gastroenterology, infectious diseases, internal medicine, interventional radiology, mental health, nephrology, neurology, neurosurgery, nutrition and dietetics, Obs and gynecology, oncology, ophthalmology, organ transplant, orthopedics, pediatrics, pain clinic, plastic and cosmetic surgery, rehabilitation, rheumatology, robotic knee replacement, robotic surgery, TAVI/TAVR, and urology. It also operates hotel under the Fortune Park Lake City Hotel name in Thane. The company was incorporated in 2002 and is based in Mumbai, India.

Visit company website →
P/E (TTM)
44.9
Forward 30.7
Earnings Growth (YoY)
+12.0%
Revenue +17.1%
ROE
+13.4%
Profit margin +12.9%
Dividend Yield
0.07%
P/B 5.6
vs 52W High
-79.9%
₹319 lo₹1,595.2 hi
79.9% below 52W high — deep Stage 4 damage
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 2
1w13w26w
Week 2 — early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-75.4%
200 DMA: ₹1,303.8 · sloping down
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
3.46x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
↓
MA20 rolling over · -39.2% vs MA50 -12.5%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
Sector has 79 Stage 2 leaders. See Health Care Stage 2 →
Industry
Hospitals & Diagnostic Centres
↑ Building
Stage 2%
59.3%
20d Δ
+7.4pp
1M return
+1.2%
3M return
+9.0%
Industry Stage-2 % · last 20 days
Industry has 16 Stage 2 leaders. See Hospitals & Diagnostic Centres Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-09-18 → 2026-08-07
S? 43w
S2 33w
S4 20w
2023-09-182026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 43w → S2 33w → S3 5w → S2 3w → S3 7w → S4 5w → S1 5w → S4 8w → S1 3w → S2 5w → S3 2w → S4 20w → S1 9w → S2 1w → S1 1w → S4 1w current
Total tracked: 149 weeks across 16 stage runs.
1M
-78.1%
3M
-74.4%
6M
-74.4%
YTD
-76.9%
1Y
-77.8%
Scan Membership
Prop Scan
Latest: 2026-07-23
Breakout Watch
Latest: 2026-07-20
8 appearances in last 60 days. First seen: 2024-07-15.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-07S4
Wk 2 · Vol —x
2026-08-06S4
Wk 2 · Vol —x
2026-08-05S4
Wk 1 · Vol —x
2026-08-04S4
Wk 1 · Vol —x
2026-08-03S4
Wk 1 · Vol —x
2026-07-31S4
Wk 1 · Vol —x
2026-07-30S41→4
Wk 1 · Vol —x
2026-07-29S1
Wk 1 · Vol —x
2026-07-28S1
Wk 1 · Vol —x
2026-07-27S12→1
Wk 1 · Vol —x
2026-07-24S2
Wk 1 · Vol —x
2026-07-23S2
Wk 1 · Vol —x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹1,169.9
200 DMA
₹1,303.8
52W High
₹1,595.2
52W Low
₹319
5D Low
₹319
Resistance levels (recent highs)
20d High
₹1,574.5
60d High
₹1,574.5
120d High
₹1,574.5
250d High
₹1,595.2
Next resistance
+391.7%
to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.